Clinical trial · Supplements / medicine · 3 Nov 2026
In mice, the experimental drug KCL-286 reduced DNA breaks and brain inflammation in an Alzheimer's model
Source: ScienceDaily
What the research found
King's College London researchers reported in FEBS Open Bio that KCL-286, an oral drug first made for spinal cord injury, reduced DNA double-strand breaks and inflammation in a mouse model of Alzheimer's disease. The drug activates a retinoic-acid receptor beta pathway. KCL-286 has already cleared a Phase 1 safety and tolerability study in people for that earlier program. That study did not test Alzheimer's disease. Jonathan Corcoran and Maria Goncalves described the mouse findings as early. Benefit against Alzheimer's in people is not known. This is not a treatment a person can ask to start, and it is not a substitute for prescribed care. DOI 10.1002/2211-5463.70284. ScienceDaily dated its page 2 November 2026. The feed time falls on 3 November in Bangkok. Not medical advice.
Evidence level: Clinical trial. This is among the stronger kinds of evidence, but one study rarely settles a question.
More supplements / medicine news
- In aged rats, two weeks of the experimental drug cinaciguat cut circulating amyloid-beta about in half and brought LDL down to youthful levels
- In 104 people with a sudden retinal-artery blockage, papaverine use lined up with better functional vision in a retrospective comparison
- A Cell Metabolism letter questions whether a fasting GLP-1 level shows how many gut L-cells a person has
- In FDA reports, caffeine and stimulant supplement use was tied to cardiac arrest about 11 times more often, and 45 percent of those cardiovascular reports were ages 18 to 34
- In 52,330 women ages 45 to 59, starting contemporary prescription hormone therapy did not raise heart, stroke, clot, or death rates over 12 years